RT Journal Article
SR Electronic
T1 Azole plasma concentrations in lung transplant recipients
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2460
VO 44
IS Suppl 58
A1 Daniela Stelzer
A1 Franziska Ihle
A1 Alexandra Weber
A1 Nikolaus Kneidinger
A1 Meis Tobias
A1 Rene Schramm
A1 Hauke Winter
A1 Lorenz Frey
A1 Michael Vogeser
A1 Juergen Behr
A1 Claus Neurohr
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P2460.abstract
AB Background:The absorption of azoles is subject to a high inter- and intra-individual variability. However, therapeutic drug monitoring [TDM] is not routinely performed. The purpose of this observation was to analyse azole plasma levels [APL] in lung transplant recipients [LTR].Methods:116 LTR of our lung transplantation [LTx] follow-up program who underwent TDM (65 male, 84 double-LTx, 3.1±3.5 years after LTx, age 49.7±14.9 years, underlying disease [ULD]: idiopathic pulmonary fibrosis [IPF; n=34; 29%], cystic fibrosis [CF; n=29; 25%], chronic obstructive pulmonary disease [COPD; n=28; 24%], other [n=25; 22%]) were evaluated. The target plasma levels [TPL] of azoles were defined as follows: Itraconazole [ITR] and Voriconazole [VOR] >1000µg/L, Posaconazole [POS] >700µg/L. APL were assayed using high performance liquid chromatography.Results:The mean APL for ITR, VOR, and POS were 715.4±866.1µg/L, 1649.2±1300.5µg/L and 903.4±780.9µg/L, respectively. Most frequent use was noted for ITR (n=55; 47%). The following results are classified by azole and ULD:View this table:Conclusion:Our data suggest that TDM is important to identify patients at risk for sub-therapeutic APL. Therefore, measuring plasma concentrations should be considered as part of the best practice management following LTx.